Boston Scientific Corporations in-depth stock price analysis indicates that the stock price has rallied 18.09% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 5.13% . Looking at the past 52 week period, the stock price is up at 51.44% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Boston Scientific Corporation has a positive value of 14.99 compared to overall market. Boston Scientific Corporation (NYSE:BSX) has tumbled 0.08% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 5.79% in the last four weeks. The stocks have underperformed the S&P 500 by 0.89% during the past week but Boston Scientific Corporation (NYSE:BSX) it has outperformed the index in 4 weeks by 3.9%.
Boston Scientific Corporation (NYSE:BSX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.14 points or 0.55% at $25.2 with 6,027,410 shares getting traded. Post opening the session at $25.36, the shares hit an intraday low of $25.2 and an intraday high of $25.43 and the price was in this range throughout the day. The company has a market cap of $34,325 million and the number of outstanding shares has been calculated to be 1,362,104,500 shares. The 52-week high of Boston Scientific Corporation (NYSE:BSX) is $25.45 and the 52-week low is $16.4.
Boston Scientific Corporation Last issued its quarterly earnings results on Feb 2, 2017. The company reported $0.30 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.29. The company had revenue of $2191.00 million for the quarter, compared to analysts expectations of $2160.14 million. The companys revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.26 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Needham on Feb 3, 2017 to Buy, Raises Price Target to $ 29 from a previous price target of $28 .
Company has reported several Insider transactions to the SEC, on Feb 8, 2017, Eric Francis Yves Thepaut (SVP & Pres, Europe) sold 23,775 shares at 24.94 per share price.On Feb 8, 2017, Keith D Dawkins (EVP, Global Chief Med. Off.) sold 80,783 shares at 25.21 per share price.On Jan 10, 2017, David A Pierce (SVP and President, Endoscopy) sold 10,232 shares at 22.24 per share price.
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The companys products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.